Faculté de Médecine
1, rue Gaston Veil
31 articles with OSE Immunotherapeutics
9/5/2019Companies from across Europe and Asia share updates on their business and pipelines.
7/25/2019Biotech and pharma companies from across the globe provide updates on company strategy and pipeline developments.
7/18/2019Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
12/26/2018Companies closed out the year with a number of appointments and hires to strengthen their leadership teams, including changes at the FDA, Melinta, CLSA, Virion, and more.
OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)
Full Antagonist Mechanism of Action Demonstrated In Vivo
Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi in Immuno-Oncology Applications
The new patent extends the U.S. protection of Tedopi to several combinations of neoepitopes (peptides from various tumourous antigens optimized to bind strongly with HLA-A2 and T lymphocyte receptors) for use in cancer treatment.
OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases
The presentation reported results from a transcriptomic analysis of colon biopsies in more than 500 patients and 100 controls in a large database available for specialized bioinformaticians.
OSE Immunotherapeutics Receives a Grant From French Government Program "Fonds Unique Interministériel" to Explore New Cytotoxic Antibodies
This collaborative program is focused on developing innovative tests to explore and to measure the cytotoxicity of monoclonal antibodies.
OSE Immunotherapeutics to Resume Accrual in Phase III Clinical Trial of Tedopi in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
There continue to be no safety concerns, as safety data remain similar to what was expected for Tedopi® based on the results of previous clinical trials.
FR104 shows immune tolerance superiority over CTLA4-Ig in humanized skin transplant model.
Selexis SA And OSE Immunotherapeutics Expand Strategic Alliance To Further Advance OSE’s OSE-172 And OSE-703 Cancer Immunotherapy Programs
OSE Immunotherapeutics Announces Temporary Pause Of Patient Accrual While Continuing Treatment For Patients Already Enrolled In Phase III Clinical Trial Of Tedopi In Advanced Lung Cancer
OSE Immunotherapeutics Presents Positive Preclinical Results And Human Ex Vivo Data For OSE-127 (Effi-7) To Support Next Clinical Applications In Inflammatory Bowel Diseases At The Federation Of Clinical Immunology Societies (FOCIS) Conference
OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration With Memorial Sloan-Kettering Cancer Center In New York
Selexis SA And OSE Immunotherapeutics Sign Commercial License Agreement To Further Advance Development Of OSE's Interleukin Receptor 7 Antagonist
OSE Immunotherapeutics Presents New Data On Anti-SIRPa (Effi-DEM), The Checkpoint Inhibitor Blocking Pro-Tumor And Suppressor Myeloid Cells At “Advances In Immuno-Oncology Congress,” London, May 15-16, 2017
OSE Immunotherapeutics Presented New Data At AACR Annual Meeting 2017 On OSE-172 (Effi-DEM), Company's Checkpoint Inhibitor Blocking Suppressive Myeloid Cells And Inducing Antitumoral Potent T Memory Response